Shirin Shamsghahfarokhi

Shirin Shamsghahfarokhi

Auto-generated profile, based on publicly available information

Shirin Shamsghahfarokhi

Department of Internal Medicine, School of Medicine, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2025 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
YSYashar Shahbaz
Yashar Shahbaz
RSRasoul Shirmohammadi
Rasoul Shirmohammadi
SSShirin Shamsghahfarokhi
Shirin Shamsghahfarokhi
HEHooman Esfahani
Hooman Esfahani
MFMobin Forghan
Mobin Forghan
MMMohammad Mousavi
Mohammad Mousavi
Cigarette smoking represents a major lifestyle risk factor for bone loss and skeletal disorders, with complex etiological mechanisms consisting both direct tissue effects and systemic alterations. Recent evidence demonstrates that tobacco smoking triggers an intricate cascade of cellular and molecular events that disrupts the delicate balance of bone remodeling, finally leading to decreased bone mass and increased fracture risk.

7 December 2025 in Journal of Nephropathology
Verified
Journal Article
Open access
PDF file
Sina Salem AhimSina Salem Ahim
Sina Salem Ahim
AEA. Emadzadeh
A. Emadzadeh
SSS. Shamsghahfarokhi
S. Shamsghahfarokhi
IAI.Z. Asoodeh
I.Z. Asoodeh
FRF. Rahbari
F. Rahbari
RAR.J. Arismani
R.J. Arismani
Recovery of renal function and structure following AKI is a complex and multifactorial process involving coordinated tubular epithelial regeneration, resolution of inflammation, restoration of microvascular integrity, and remodeling of the extracellular matrix. Clinical recovery is variable and influenced by injury severity, comorbidities, and therapeutic interventions. Advances in biomarkers and imaging techniques enhance early prediction and monitoring of recovery trajectories. Although no definitive therapies currently exist to reliably speed recovery, promising approaches, including stem cell secretome administration and growth factor modulation, are in development. Long-term consequences of incomplete structural repair highlight the importance of sustained patient followup after apparent recovery from AKI. Keywords: Chronic kidney disease, Acute kidney injury, Renal recovery, Kidney function, Renal structure, Nephron regeneration, Tubular repair, Histology

29 June 2026 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
KSKianoush Saberi
Kianoush Saberi
NDNilufar Dehkanova
Nilufar Dehkanova
NRNodira Rashidova
Nodira Rashidova
MKMalika Khaldarbekova
Malika Khaldarbekova
DRDilnora Raxmatova
Dilnora Raxmatova
SSShirin Shamsghahfarokhi
Shirin Shamsghahfarokhi
Hypertension remains the leading modifiable risk factor for global cardiovascular mortality, disproportionately burdening resource-limited settings where access to consistent pharmacotherapy is hindered by cost, supply chains, healthcare infrastructure gaps, and polypharmacy risks. While medications are essential, over-reliance on them neglects the foundational role of lifestyle modification as a potent, underutilized therapeutic pillar. This review, argues for a paradigm shift towards lifestyle precision medicine in resource-limited settings through moving beyond one-size-fits-all advice to context-specific, feasible, and culturally resonant behavioral interventions integrated into primary care. Lifestyle precision medicine tailors dietary patterns, physical activity, stress reduction, and sodium reduction to individual socioeconomic realities, cultural preferences, literacy levels, and environmental constraints. On world hypertension day, we urge global health agencies, governments, and researchers to prioritize funding and policy reforms that position lifestyle precision medicine not as a luxury, but as an equitable, essential component of hypertension care in resource-limited settings. Precision lies not in genomics, but in contextual intelligence, transforming evidence into action that resonates where people live and work.

4 November 2025 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
MFMaryam Farajisani
Maryam Farajisani
SSShirin Shamsghahfarokhi
Shirin Shamsghahfarokhi
ZMZahra Hamidi Madani
Zahra Hamidi Madani
ZZZeinab Zamanpour
Zeinab Zamanpour
HRHamid Rastad
Hamid Rastad
FDForoohar Darabi
Foroohar Darabi
Introduction: Gestational diabetes mellitus (GDM) is a common metabolic disorder during pregnancy, and the triglyceride-glucose (TyG) index is among the indicators that can predict the occurrence of gestational diabetes. Accordingly, our goal was to examine the relationship between the TyG index and GDM. Materials and Methods: Databases of Scopus, PubMed, Embase, Web of Science, Cochrane, and Google Scholar search engine were used for articles published until September 5, 2025. Data was analyzed using STATA 14. Tests with P values<0.05 were considered statistically significant. Results: High TyG index in general (OR:1.77, 95% CI: 1.56, 2), in the second one-third (OR:1.90, 95% CI: 1.08, 3.36), third one-third (OR:3.94, 95% CI: 2.07, 7.50), second quartile (OR:1.24, 95% CI: 1.07, 1.44), third quartile (OR:1.58, 95% CI: 1.28, 1.94), fourth quartile (OR:2.42, 95% CI: 1.85, 3.17), second quantile (OR:1.23, 95% CI: 1.05, 1.43), third quantile (OR:1.44, 95% CI: 1.23, 1.68), fourth quantile (OR:2.15, 95% CI: 1.41, 3.28), fifth quantile (OR:2.92, 95% CI: 1.96, 4.37) increased the risk of GDM. Furthermore, high TyG index levels increased the risk of GDM in China (OR:1.84, 95% CI: 1.59, 2.13), Korea (OR:1.43, 95% CI: 1.08, 1.89), cohort studies (OR:1.82, 95% CI: 1.60, 2.07), women groups with mean ages ≥ 35 (OR:2.54, 95% CI: 1.84, 3.51), and women with BMIs ≥ 25 (OR:2.56, 95% CI: 2.06, 3.18). Conclusion: High TyG index levels increased the risk of GDM by about 77%, and higher TyG index levels led to even higher possibilities of GDM occurrence. Additionally, obese and overweight women and those aged ≥ 35 were more exposed to this disease than other women. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251143086) and Research Registry (UIN: reviewregistry2046) websites.

17 August 2025 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
SASajad Ataei Azimi
Sajad Ataei Azimi
AKAsaad Abass Fadhel Khalif
Asaad Abass Fadhel Khalif
ASAhmadreza Siyasari
Ahmadreza Siyasari
ZBZahra Bazargani
Zahra Bazargani
PKPeyman Khajehnabi
Peyman Khajehnabi
SSShirin Shamsghahfarokhi
Shirin Shamsghahfarokhi
Chronic kidney disease (CKD) is a global health burden, often complicated by anemia due to impaired erythropoietin production and iron dysregulation. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has emerged as a promising therapeutic option for managing anemia in CKD patients. By stabilizing hypoxia-inducible factors, vadadustat enhances endogenous erythropoietin production and improves iron metabolism, offering a novel approach to treating CKD-associated anemia. Recent clinical trials demonstrate that vadadustat effectively increases hemoglobin levels, reduces the need for erythropoiesis-stimulating agents (ESAs), and improves patients’ quality of life. However, concerns regarding its safety, including potential risks of thromboembolic events and hypertension, warrant careful patient selection and monitoring. Comparative analyses with standard therapies, such as ESAs and other HIF-PH inhibitors, highlight vadadustat’s advantages in terms of oral administration and cost-effectiveness, while also identifying areas for further research.

4 November 2025 in Immunopathologia Persa
Verified
Journal Article
Closed access
SASajad Ataei Azimi
Sajad Ataei Azimi
ASAhmadreza Siyasari
Ahmadreza Siyasari
SNSara Abutalebi Nasrabad
Sara Abutalebi Nasrabad
ASArvin Saboori
Arvin Saboori
RBRoya Biglarifar
Roya Biglarifar
ABAzar Baradaran
Azar Baradaran
Introduction: Uterine cervical cancer remains a major public health concern worldwide, ranking as the fourth most common cancer among women. Despite advances in prevention and treatment, significant disparities in incidence and mortality persist, largely reflecting underlying socioeconomic inequalities. The human development index (HDI), a composite measure of life expectancy, education, and per capita income, offers a critical lens for examining these disparities on a global scale. Objectives: This ecological study aimed to investigate the patterns of cervical cancer incidence and mortality across countries stratified by HDI in 2022, highlighting the persistent influence of socioeconomic development on disease burden. Materials and Methods: This ecological study utilized data from the International Agency for Research on Cancer (IARC) and the Global Cancer Observatory (GLOBOCAN) project for the year 2022. Incidence and mortality statistics for uterine cervical cancer were extracted for countries worldwide and stratified according to the HDI categories. Comparative analyses were then performed to evaluate differences in uterine cancer incidence and mortality across varying HDI levels. Results: The results showed that countries classified as very high HDI demonstrated the most favorable outcomes in the context of uterine cervical cancer, displaying the smallest proportions of both newly diagnosed cases and resultant mortality. Conversely, as the HDI categorization shifts downwards, transitioning from the designation of high to medium, and subsequently to low, a corresponding and gradual escalation becomes evident in the rates of both the incidence of new cervical cancer diagnoses and the rates of mortality stemming from this particular disease. Conclusion: In conclusion, the significant socioeconomic disparities identified in uterine cervical cancer incidence and mortality underscore the urgent need for targeted interventions in lower HDI countries. Addressing these inequities through improved access to prevention, screening, and treatment is essential to reduce the disproportionate burden and promote global health equity in cervical cancer outcomes.